Does Resmetirom Interact with Atorvastatin?
CDI records a major classification for Resmetirom and Atorvastatin. The stored summary is: REZDIFFRA increases plasma concentrations of atorvastatin; limit daily dosage to 40 mg to reduce risk of statin-related adverse reactions. The mechanism involves resmetirom inhibits cyp2c8-mediated metabolism of atorvastatin. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
- Severity
- Major
- Resmetirom Class
- Thyroid Hormone Receptor beta Agonist
- Management
- Close medical supervision required
- Data Source
- U.S. FDA via OpenFDA
Recorded Mechanism
Resmetirom inhibits CYP2C8-mediated metabolism of atorvastatin
What To Tell Your Doctor or Pharmacist
If you are taking Resmetirom and your doctor is considering prescribing Atorvastatin (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask how frequently you should be monitored while these are co-prescribed
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider